1.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 to 65
Sponsor: Other
Protocol IDs: MCC-14178, NCT00361140
|
|
2.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 4 to 70
Sponsor: Other
Protocol IDs: RPCI-RP-9815, NCI-V99-1527, NCT00003816, RP 98-15
|
|
3.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 35 and under
Sponsor: Other
Protocol IDs: 2000LS040, MT2000-12, 0005M52481, NCT00176839
|
|
4.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 12 to 55
Sponsor: Pharmaceutical / Industry
Protocol IDs: GC P#02.01.001, NCT00469729
|
|
5.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 4 and over
Sponsor: NCI
Protocol IDs: RPCI-I-72806, I 72806, NCT00536601
|
|
6.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: Other
Protocol IDs: UMN-MT2006-13, MT2006-13, NCT00630565
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 54 and under
Sponsor: Other
Protocol IDs: 0107M05202, MT2001-02, NCT00176930
|
|
8.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 65 and under
Sponsor: NCI, NHLBI
Protocol IDs: FHCRC-1992.00, 6170, NCT00322101, NHLBI-K23-HL084054-01A1
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 16 to 65
Sponsor: NCI
Protocol IDs: CBMTG-0601, NCT00438958
|
|
10.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 65 and under
Sponsor: Other
Protocol IDs: 2005-0366, NCT00469144
|
|
11.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 50 to 75
Sponsor: NCI, Other
Protocol IDs: SU-11122007-874, 97843, BMT190, NCT00568633, NCT00568633
|
|
12.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 2 to 55
Sponsor: NCI, NHLBI
Protocol IDs: 385, BMT CTN 0402, U01 HL069294-05, NCT00406393
|
|
13.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 2008-0503, NCT00887068
|
|
14.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: Other
Protocol IDs: H8713, NCT00058825
|
|
15.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 12 to 60
Sponsor: Pharmaceutical / Industry
Protocol IDs: CB001, NCT00089596
|
|
16.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Under 75
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: FHCRC-1825.00, 5605, SUPERGEN-FHCRC-1825.00, NCT00096161
|
|
17.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 16 to 50
Sponsor: Other
Protocol IDs: FHCRC-1809.00, 5602, NCT00119366
|
|
18.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: NCI
Protocol IDs: UMN-2004LS042, UMN-MT2003-23, UMN-IRB-0405M60481, NCT00303667
|
|
19.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 06-065, X05175, NCT00369226
|
|
20.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: Other
Protocol IDs: 2005-0508, NCT00402558
|
|
21.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Under 55
Sponsor: NCI
Protocol IDs: MSKCC-06125, NCT00423514
|
|
22.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 04U.115, NCT00429416
|
|
23.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: FHCRC-2064.00, 6294, NCT00453388
|
|
24.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 69
Sponsor: NCI
Protocol IDs: NCI-07-C-0195, 07-C-0195, NCT00520130
|
|
25.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 2 to 55
Sponsor: NCI
Protocol IDs: CHNMC-05013, 05013, NCT00540995
|
